FCMI
NGM

Foresite Capital Management IV’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Foresite Capital Management IV’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-471,269
Closed -$6.9M – 24
2019
Q2 		$6.9M Buy
+471,269
New +$6.9M 1.95% 15

Other funds holding NGM

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
JRP
Jasper Ridge Partners Menlo Park, California $4.69B AUM 31.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Foresite Capital Management IV's NGM Position: Q3 2019 in Review

Foresite Capital Management IV sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2019, closing a stake of 471,269 shares — an estimated $6.9M sold.

Foresite Capital Management IV first reported a position in NGM in Q2 2019 and held it in 1 quarter. The position peaked at $6.9M in Q2 2019. 51 funds tracked by Wall St. Rank hold NGM as of Q3 2019.

  • Foresite Capital Management IV reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Foresite Capital Management IV sold 471,269 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $6.9M.
  • Foresite Capital Management IV first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Foresite Capital Management IV's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $6.9M in Q2 2019.
  • 51 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Foresite Capital Management IV's 13F filing for Q3 2019, filed 13 Nov 2019.